Moving towards malaria elimination in southern Mozambique: Cost and cost-effectiveness of mass drug administration combined with intensified malaria control

PLoS ONE

Volumn 15, Issue 7, 2020, Pages

  Cirera, Laia ^a   Galatas, Beatriz ^a,b   Alonso, Sergi ^c   Paaijmans, Krijn ^a,b,d   Mamuquele, Miler ^b   Martí Soler, Helena ^a   Guinovart, Caterina ^a   Munguambe, Humberto ^b   Luis, Fabião ^b   Nhantumbo, Hoticha ^b   Montañà, Júlia ^a,b   Bassat, Quique ^a,b,e,f   Candrinho, Baltazar ^g   Rabinovich, Regina ^a,h   Macete, Eusebio ^b,i   Aide, Pedro ^b,i   Alonso, Pedro ^a,b   Saúte, Francisco ^b   Sicuri, Elisa ^a,j  

^a CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^b Manhiça Health Research Center   (Mozambique)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d ARIZONA STATE UNIVERSITY   (United States)

^e UNIVERSITY OF BARCELONA   (Spain)

^f INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^g MINISTRY OF HEALTH   (Mozambique)

^h HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

ⁱ INSTITUTO NACIONAL DE SAÚDE   (Mozambique)

^j IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST; COST EFFECTIVENESS ANALYSIS; DISABILITY-ADJUSTED LIFE YEAR; DISEASE ELIMINATION; GROSS NATIONAL PRODUCT; HUMAN; INDOOR RESIDUAL SPRAYING; MALARIA; MALARIA CONTROL; MASS DRUG ADMINISTRATION; MORTALITY RATE; MOZAMBIQUE; SENSITIVITY ANALYSIS; TREND STUDY; COST BENEFIT ANALYSIS; ECONOMICS;

COST-BENEFIT ANALYSIS; HUMANS; MALARIA; MASS DRUG ADMINISTRATION; MOZAMBIQUE;

EID: 85087729954     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0235631     Document Type: Article

References (48)

1. WHO. Eliminating Malaria. World Health Organization. 2016.
2. Alonso PL, Brown G, Arevalo-Herrera M, Binka F, Chitnis C, Collins F, et al. A research agenda to underpin malaria eradication. PLoS Med. 2011; 8(1):e1000406. Epub 2011/02/12. https://doi.org/10.1371/journal.pmed.1000406 PMID: 21311579.
3. Barrett S. Economic considerations for the eradication endgame. Philos Trans R Soc Lond B Biol Sci. 2013; 368(1623). Epub 2013/06/27. https://doi.org/10.1098/rstb.2012.0149 PMID: 23798697.
4. Bleakley H. Disease and Development: Evidence from Hookworm Eradication in the American South. Q J Econ. 2007; 122(1):73–117. Epub 2007/01/01. https://doi.org/10.1162/qjec.121.1.73 PMID: 24146438.
5. Lucas AM. Malaria Eradication and Educational Attainment: Evidence from Paraguay and Sri Lanka. American economic journal Applied economics. 2010; 2(2):46–71. https://doi.org/10.1257/app.2.2.46 PMID: 23946866.
6. Cutler D, Fung W, Kremer M, Singhal M, Vogl T. Early-life malaria exposure and adult outcomes: Evidence from malaria eradication in India. American Economic Journal: Applied Economics. 2010; 2(72).
7. Kim YE, Sicuri E, Tediosi F. Financial and Economic Costs of the Elimination and Eradication of Onchocerciasis (River Blindness) in Africa. PLoS Negl Trop Dis. 2015; 9(9):e0004056. Epub 2015/09/12. https://doi.org/10.1371/journal.pntd.0004056 PMID: 26360917.
8. Kastner RJ, Sicuri E, Stone CM, Matwale G, Onapa A, Tediosi F. How much will it cost to eradicate lymphatic filariasis? An analysis of the financial and economic costs of intensified efforts against lymphatic filariasis. PLoS Negl Trop Dis. 2017; 11(9):e0005934. Epub 2017/09/28. https://doi.org/10.1371/journal.pntd.0005934 PMID: 28949987.
9. Barrett S. The smallpox eradication game. Public Choice. 2006; 130:179–207.
10. Sabot O, Cohen JM, Hsiang MS, Kahn JG, Basu S, Tang L, et al. Costs and financial feasibility of malaria elimination. Lancet. 2010; 376(9752):1604–15. https://doi.org/10.1016/S0140-6736(10)61355-4 PMID: 21035839.
11. Shah NK. Assessing strategy and equity in the elimination of malaria. PLoS Med. 2010; 7(8):e1000312. Epub 2010/08/07. https://doi.org/10.1371/journal.pmed.1000312 PMID: 20689859.
12. Smith RD. Global public goods and health. Bull World Health Organ. 2003; 81(7):475. Epub 2003/09/ 16. PMID: 12973638.
13. Churcher TS, Cohen JM, Novotny J, Ntshalintshali N, Kunene S, Cauchemez S. Public health. Measuring the path toward malaria elimination. Science. 2014; 344(6189):1230–2. https://doi.org/10.1126/science.1251449 PMID: 24926005.
14. WHO. Global technical strategy for malaria 2016–2030. The World Health Organization, 2015.
15. WHO. Mass drug administration, mass screening and treatment and focal screening and treatment for malaria. 2015.
16. Poirot E, Skarbinski J, Sinclair D, Kachur SP, Slutsker L, Hwang J. Mass drug administration for malaria. Cochrane Database Syst Rev. 2013;(12):CD008846. https://doi.org/10.1002/14651858.CD008846.pub2 PMID: 24318836.
17. Newby G, Hwang J, Koita K, Chen I, Greenwood B, von Seidlein L, et al. Review of mass drug administration for malaria and its operational challenges. Am J Trop Med Hyg. 2015; 93(1):125–34. https://doi.org/10.4269/ajtmh.14-0254 PMID: 26013371.
18. von Seidlein L, Peto TJ, Landier J, Nguyen TN, Tripura R, Phommasone K, et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in Southeast Asia: A cluster randomised trial. PLoS Med. 2019; 16(2):e1002745. Epub 2019/02/16. https://doi.org/10.1371/journal.pmed.1002745 PMID: 30768615 stipend as a Specialty Consulting Editor for PLOS Medicine and serves on the journal’s Editorial Board. NJW is a member of the Editorial Board of PLOS Medicine.
19. Eisele TP, Bennett A, Silumbe K, Finn TP, Chalwe V, Kamuliwo M, et al. Short-term Impact of Mass Drug Administration With Dihydroartemisinin Plus Piperaquine on Malaria in Southern Province Zambia: A Cluster-Randomized Controlled Trial. J Infect Dis. 2016; 214(12):1831–9. Epub 2016/12/08. https://doi.org/10.1093/infdis/jiw416 PMID: 27923947.
20. Deng C, Huang B, Wang Q, Wu W, Zheng S, Zhang H, et al. Large-scale Artemisinin-Piperaquine Mass Drug Administration With or Without Primaquine Dramatically Reduces Malaria in a Highly Endemic Region of Africa. Clin Infect Dis. 2018; 67(11):1670–6. Epub 2018/05/31. https://doi.org/10.1093/cid/ ciy364 PMID: 29846536.
21. Aide P, Candrinho B, Galatas B, Munguambe K, Guinovart C, Luis F, et al. Setting the scene and generating evidence for malaria elimination in Southern Mozambique. Malar J. 2019; 18(1):190. Epub 2019/ 06/07. https://doi.org/10.1186/s12936-019-2832-9 PMID: 31170984.
22. Galatas B, Saúte F, Martí-Soler H, Montañà J, Guinovart C, Munguambe H, et al. The Magude project: a before-after study aiming to eliminate malaria in southern Mozambique. Manuscript under review (PLos Med). 2020.
23. WHO. Review of delivery cost data on mass adrug administration for malaria. Geneva: 2015.
24. Barrett S. Polio eradication: strengthening the weakest links. Health Aff (Millwood). 2009; 28(4):1079–90. https://doi.org/10.1377/hlthaff.28.4.1079 PMID: 19597207.
25. Galatas B, Nhacolo A, Marti H, Munguambe H, Jamise E, Guinovart C, et al. Demographic and health community-based surveys to inform a malaria elimination project in Magude district, southern Mozambique. BMJ Open. 2020; 10(5):e033985. https://doi.org/10.1136/bmjopen-2019-033985 PMID: 32371510
26. MISAU. Normas de Tratamento de Malária em Moçambique. Direcção Nacional de Saúde Pública, Maputo 2017.
27. WHO. WHO guide to identifying the economic consequences of disease and injury. 2009.
28. WHO. WHO guide to cost-effectiveness analysis. Geneva2003.
29. Drummond M, Sculpher M, Claxton K, Stoddart G, Torrance G. Methods for the Economic Evaluation of Health Care Programmes (4th ed). Press OU, editor. Oxford, UK2015.
30. OANDA. Historical currency converter 2019 2019 [cited 2019 May 3]. https://www.oanda.com/fx-forbusiness/historical-rates.
31. IMF. World Economic Outlook database. Consumer price index by country 2018 [cited 2019 May 3]. http://data.imf.org/regular.aspx?key=61015892.
32. Cico A, Johns B. PMI IRS Country Programs: 2017 Comparative Cost Analysis. 2018.
33. Sicuri E, Bardaji A, Nhampossa T, Maixenchs M, Nhacolo A, Nhalungo D, et al. Cost-effectiveness of intermittent preventive treatment of malaria in pregnancy in southern Mozambique. PLoS One. 2010; 5 (10):e13407. Epub 2010/10/27. https://doi.org/10.1371/journal.pone.0013407 PMID: 20976217.
34. WHO. WHO Methods and Data Sources for Global Burden of Disease Estimates 2000–2015. 2017.
35. WageIndicator. WageIndicator 2019—Meusalario.org/Mocambique—Salários dos Médicos e Enfermeiros 2017 2019. https://meusalario.org/mocambique/salario/sector-publico-mocambique/salariosdo-sector-de-saude.
36. Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD, et al. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force —6. Value Health. 2012; 15(6):835–42. Epub 2012/09/25. https://doi.org/10.1016/j.jval.2012.04.014 PMID: 22999133.
37. WHO. World Health Organization cost-effectiveness thresholds. hhttp://www.who.int/choice/costs/CER_thresholds/en/index.htmli. [Accessed March 20,2019].
38. Woods B, Revill P, Sculpher M, Claxton K. Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research. Value Health. 2016; 19(8):929–35. Epub 2016/12/19. https://doi.org/10.1016/j.jval.2016.02.017 PMID: 27987642.
39. INE. Instituto Nacional de Estadística de Moçambique. [Accessed on 24th August, 2019: http://www.ine.gov.mz/estatisticas/estatisticas-demograficas-e-indicadores-sociais]. 2019.
40. WHO. Malaria Surveillance, Monitoring & Evaluation: A Reference Manual. 2018. 2018.
41. Goodman CA, Coleman PG, Mills AJ. Cost-effectiveness of malaria control in sub-Saharan Africa. Lancet. 1999; 354(9176):378–85. Epub 1999/08/07. https://doi.org/10.1016/s0140-6736(99)02141-8 PMID: 10437867.
42. Morel CM, Lauer JA, Evans DB. Cost effectiveness analysis of strategies to combat malaria in developing countries. BMJ. 2005; 331(7528):1299. Epub 2005/11/12. https://doi.org/10.1136/bmj.38639.702384.AE PMID: 16282381.
43. Elbasha EH, Messonnier ML. Cost-effectiveness analysis and health care resource allocation: decision rules under variable returns to scale. Health Econ. 2004; 13(1):21–35. Epub 2004/01/16. https://doi.org/10.1002/hec.793 PMID: 14724891.
44. Kastner RJ, Stone CM, Steinmann P, Tanner M, Tediosi F. Lessons Learned From Developing an Eradication Investment Case for Lymphatic Filariasis. Adv Parasitol. 2016; 94:393–417. https://doi.org/10.1016/bs.apar.2016.08.004 PMID: 27756458.
45. Turner HC, Toor J, Hollingsworth TD, Anderson RM. Economic evaluations of mass drug administration: The importance of economies of scale and scope. Clin Infect Dis. 2017. Epub 2017/11/11. https://doi.org/10.1093/cid/cix1001 PMID: 29126255.
46. CNTD. Mozambique: Integrated MDA implementation. Center for Neglected Tropical Diseases. 2019. https://cntd.lstmed.ac.uk/our-work/case-studies/mozambique-integrated-mda-implementation.
47. Johns B, Torres TT, Who C. Costs of scaling up health interventions: a systematic review. Health Policy Plan. 2005; 20(1):1–13. Epub 2005/02/04. https://doi.org/10.1093/heapol/czi001 PMID: 15689425.
48. Fitzpatrick C, Fleming FM, Madin-Warburton M, Schneider T, Meheus F, Asiedu K, et al. Benchmarking the Cost per Person of Mass Treatment for Selected Neglected Tropical Diseases: An Approach Based on Literature Review and Meta-regression with Web-Based Software Application. PLoS Negl Trop Dis. 2016; 10(12):e0005037. Epub 2016/12/06. https://doi.org/10.1371/journal.pntd.0005037 PMID: 27918573.